- Home
- MIST vs CNTB Comparison
MIST vs CNTB Comparison
Compare MIST & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIST
- CNTB
- Stock Information
- Founded
- MIST 2003
- CNTB 2012
- Country
- MIST Canada
- CNTB United States
- Employees
- MIST N/A
- CNTB N/A
- Industry
- MIST Biotechnology: Pharmaceutical Preparations
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- MIST Health Care
- CNTB Health Care
- Exchange
- MIST Nasdaq
- CNTB Nasdaq
- Market Cap
- MIST 164.9M
- CNTB 94.2M
- IPO Year
- MIST N/A
- CNTB 2021
- Fundamental
- Price
- MIST $1.91
- CNTB $1.60
- Analyst Decision
- MIST Strong Buy
- CNTB Strong Buy
- Analyst Count
- MIST 3
- CNTB 2
- Target Price
- MIST $6.33
- CNTB $7.50
- AVG Volume (30 Days)
- MIST 1.5M
- CNTB 89.9K
- Earning Date
- MIST 11-11-2025
- CNTB 11-30-2025
- Dividend Yield
- MIST N/A
- CNTB N/A
- EPS Growth
- MIST N/A
- CNTB N/A
- EPS
- MIST N/A
- CNTB N/A
- Revenue
- MIST N/A
- CNTB $1,965,000.00
- Revenue This Year
- MIST N/A
- CNTB N/A
- Revenue Next Year
- MIST N/A
- CNTB $453,067.90
- P/E Ratio
- MIST N/A
- CNTB N/A
- Revenue Growth
- MIST N/A
- CNTB N/A
- 52 Week Low
- MIST $0.63
- CNTB $1.23
- 52 Week High
- MIST $2.75
- CNTB $2.20
- Technical
- Relative Strength Index (RSI)
- MIST 46.50
- CNTB 44.89
- Support Level
- MIST $1.85
- CNTB $1.55
- Resistance Level
- MIST $2.14
- CNTB $1.72
- Average True Range (ATR)
- MIST 0.11
- CNTB 0.15
- MACD
- MIST -0.03
- CNTB -0.02
- Stochastic Oscillator
- MIST 19.66
- CNTB 9.64
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.